Stone prevention and the patient: An expert’s view
“Even in patients that have only been single-stone formers, especially those that have required surgical stone removal, we believe that medical prevention is warranted to prevent recurrent stones,” says Glenn M. Preminger, MD.
In this video, Glenn M. Preminger, MD, assesses the challenges and methods involved in stone prevention. Preminger is presenting the John K. Lattimer Lecture, "Kidney stones: Is prevention possible?" at the 2021 American Urological Association annual meeting. Preminger is a urologist and professor of surgery at Duke University Medical Center, Durham, North Carolina.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
